08/21/2026
Your patient spent years hearing their symptoms were stress, or nothing the scans could confirm. Now they have a name for a rare autoinflammatory disease, an off-label biologic with a thin evidence base, and a decision only they can make.
That decision doesn't come with a settled playbook. Most of what's known about treatment response in these conditions comes from case reports and small series, not large trials. The patient is being asked to weigh disease control against everything it costs them outside the clinic: sometimes a career, sometimes the chance at a family, always some version of an ordinary day.
This is where the principles that anchor clinical ethics, autonomy, beneficence, non-maleficence, and justice, stop being theoretical. They're the operating logic behind every treatment escalation conversation, every informed consent process for a therapy without long-term safety data, every quality-of-life discussion about whether tighter control is worth its cost.
A 2022 paper in HEC Forum, by Weidmann-Hügle and Monteverde, argues clinical ethics consultation has been slow to catch up to this reality. The biomedical model most consultations run on treats autonomy as a single judgment made at a single moment. Patients living with chronic illness for years function as something closer to lay experts of their own condition. When ethics conversations discount that expertise, the authors call it epistemic injustice: treating years of self-knowledge as less credible than a chart note.
A related body of work on rare disease ethics finds something similar from the patient side. Patients report feeling dismissed before diagnosis and unheard after it, not through clinician carelessness but because most training never covers a condition this uncommon. The proposed fix wasn't more paternalism to offset the uncertainty. It was more partnership: staying open-minded, treating patients as capable of navigating their own care, and supporting autonomy instead of assuming it.
Clinical ethics education has spent decades centered on the ICU, the ventilator, the family gathered around a bed. For rare and autoinflammatory disease patients, that moment may come. But the ethical terrain starts well before it, in the ordinary exam room conversation about a treatment nobody can fully predict.
In AEI's State Requirements Course, Adam Marks, MD, MPH, FAAHPM, faculty ethicist at the University of Michigan, walks through autonomy, surrogate decision-making, and the limits of medical futility through real-world end-of-life cases. Attend accredited CME across 55+ destinations, and bring a framework built for the ethics conversations that happen long before, and long after, the ICU.
The Radiology Update offers medical continuing education credits in beautiful vacation destinations. View available courses today.
